Member Info for draft

No need for the turner and poop note. We have better research than that nonsense.

We will probably start getting updates from evotec as each phase progresses. Be funny if evotec say here is 20mill. We want Nuvec.

20mill mcap sounds more reasonable given Evotec are involved.

Scientific will expand its viral vector services with the construction of a facility in Plainville, Massachusetts. The $180 million project will more than double Thermo Fisher’s capacity to serve developers of gene therapies and vaccines. The company expanded similar operations last year in Alachua, Florida. It also has viral vector operations in Lexington and Cambridge, Massachusetts. Thermo Fisher expects the 26,900 m2 facility in Plainville to be

I really think n4p is going to go sky high.

https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options

Evotec is on the list and we know n4p took the covid plasmid from USA NHI . Kaboooooommm

Industry

AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Evotec
GlaxoSmithKline
Johnson & Johnson
KSQ Therapeutics
Eli Lilly and Company
Merck & Co., Inc.
Novartis
Pfizer
Roche
Sanofi
Takeda
Vir Biotechnology

I suspect last 6 months trading has been good. They ll give a decent trading update.

Im just going to hold. See you at 20p plus.

Give it a bit of time, bun in the oven , this will do a novacyte. Not many low mcap plays left in the barrel.

Yeah there probs will be some flipping but then that ll be from the unresearched people. Ppl who've done their research like Myles I suspect would hold given the 500% rises at avacta, novacyte etc. Nothing goes up in a straight line but theres a clear value disconnect here now.

No way. You got Evotec proving, global patents, a need for a better delivery system, huge 100million deals going on, you d be MAD to sell or trade this I reckon.

And some non sticky flippers and this should be like 20p plus in my opinion.

Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with e.g. with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases and with Celgene in the areas neurodegenerative diseases and oncology.

I reckon big pharma will take out Nuvec and fast. Why build all those viral manufacturing plants if you got no product to build? Enter Nuvec.

Billion $ takeovers and new viral vector manufacturing plants being built by Merck and Thermofisher. N4p only 5mill mcap. This is in your face now a 5 to 10 bagger. Im holding. This could go berserk. Market needs to wake up. Thermofisher spending $180 million on a viral vector plant.

Look at the takeover premiums in this industry. Catalent (NYSE: CTLT) spent $1.2 billion to acquire viral vector and gene therapy manufacturer Paragon Bioservices in April last year, and, in March 2019, Thermo Fisher Scientific (NYSE: TMO) invested $1.7 billion to buy Brammer Bio, also a leader in viral vector manufacturing for gene and cell therapies.

Also, Swiss pharma giant Novartis’ (NOVN: VX) AveXis unit, behind the gene therapy Zolgensma (onasemnogene abeparvovec-xioi), in April last year signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, USA.

https://www.prnewswire.co.uk/news-releases/merck-boosts-commercial-viral-vector-and-gene-therapy-manufacturing-capacity-896993730.html

Thermo Fisher to double viral vector services with $180 million project
by Rick Mullin
MAY 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

https://www.biopharma-reporter.com/Article/2020/05/18/Thermo-Fisher-to-build-viral-vector-plant